Clinical Trial Update: A Study of SHR-A1811 as Neoadjuvant Treatment for Patients With HR-Positive, Low HER2 Expression Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial assessing SHR-A1811 as neoadjuvant therapy for HR-positive, HER2-low breast cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Hormone Receptor-positive Breast Cancer
• Low Breast Cancer

Drugs mentioned

• SHR-A1811

Snippet

Sponsor: Henan Cancer Hospital | Conditions: HER2 Low Breast Carcinoma | Phase 2 | Status: RECRUITING